Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide
(NO) production. Both are associated with poor outcome. This study will examine the safety
and effect of escalating doses of arginine in falciparum malaria. It will determine whether
arginine can increase NO production and have an effect on NO-dependent physiological
measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will
return plasma arginine concentration to normal/supranormal levels; will increase systemic and
exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological
measures of relevance to malaria.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Menzies School of Health Research
Collaborators:
MSHR National Health and Medical Research Council, Australia National Institute of Health Research and Development, Ministry of Health Republic of Indonesia Rumah Sakit Mitra Masyarakat Hospital University of Sydney University of Utah Wellcome Trust